LifeStance Health Group (NASDAQ:LFST) Director Robert Bessler Sells 5,101 Shares

LifeStance Health Group, Inc. (NASDAQ:LFST) Director Robert Bessler sold 5,101 shares of the company’s stock in a transaction dated Tuesday, April 21st. The shares were sold at an average price of $7.01, for a total transaction of $35,758.01. Following the sale, the director owned 1,309,397 shares in the company, valued at $9,178,872.97. This represents a 0.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

LifeStance Health Group Trading Up 1.2%

LFST opened at $6.99 on Friday. The firm has a market cap of $2.72 billion, a P/E ratio of 349.67 and a beta of 1.13. LifeStance Health Group, Inc. has a 12 month low of $3.74 and a 12 month high of $8.09. The company has a current ratio of 1.65, a quick ratio of 1.65 and a debt-to-equity ratio of 0.17. The stock has a 50-day moving average of $6.73 and a 200 day moving average of $6.54.

LifeStance Health Group (NASDAQ:LFST) last issued its quarterly earnings data on Wednesday, February 25th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.02). The company had revenue of $382.20 million for the quarter, compared to analysts’ expectations of $378.51 million. LifeStance Health Group had a net margin of 0.68% and a return on equity of 0.65%. The company’s revenue for the quarter was up 17.4% on a year-over-year basis. During the same quarter last year, the company earned ($0.01) earnings per share. As a group, research analysts forecast that LifeStance Health Group, Inc. will post 0.09 EPS for the current year.

LifeStance Health Group declared that its board has authorized a stock buyback plan on Wednesday, February 25th that authorizes the company to buyback $100.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 3.6% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s board believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. KeyCorp raised their price target on LifeStance Health Group from $8.00 to $9.00 and gave the stock an “overweight” rating in a research report on Thursday, February 26th. Jefferies Financial Group upgraded shares of LifeStance Health Group to a “strong-buy” rating in a research report on Thursday, March 12th. BTIG Research raised their target price on shares of LifeStance Health Group from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, February 2nd. Canaccord Genuity Group raised their target price on shares of LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Finally, Weiss Ratings raised shares of LifeStance Health Group from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Friday, February 27th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, LifeStance Health Group presently has an average rating of “Moderate Buy” and an average target price of $9.83.

Institutional Trading of LifeStance Health Group

Several institutional investors and hedge funds have recently made changes to their positions in the business. Royal Bank of Canada boosted its stake in shares of LifeStance Health Group by 63.4% during the first quarter. Royal Bank of Canada now owns 70,248 shares of the company’s stock valued at $468,000 after purchasing an additional 27,244 shares during the period. AQR Capital Management LLC increased its stake in LifeStance Health Group by 223.0% in the 1st quarter. AQR Capital Management LLC now owns 51,500 shares of the company’s stock worth $343,000 after buying an additional 35,554 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in LifeStance Health Group by 3.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 142,950 shares of the company’s stock valued at $952,000 after buying an additional 4,169 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in LifeStance Health Group by 1.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 615,652 shares of the company’s stock valued at $4,100,000 after buying an additional 11,331 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in LifeStance Health Group by 10.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 550,657 shares of the company’s stock valued at $2,847,000 after buying an additional 51,154 shares during the period. 85.50% of the stock is currently owned by institutional investors.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.